Quest Diagnostics SG&A Expenses 2012-2026 | DGX
Quest Diagnostics annual/quarterly sg&a expenses history and growth rate from 2012 to 2026. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Quest Diagnostics sg&a expenses for the quarter ending March 31, 2026 were $504M, a 5.88% increase year-over-year.
- Quest Diagnostics sg&a expenses for the twelve months ending March 31, 2026 were $1.995B, a 10.47% increase year-over-year.
- Quest Diagnostics annual sg&a expenses for 2025 were $1.967B, a 11.13% increase from 2024.
- Quest Diagnostics annual sg&a expenses for 2024 were $1.77B, a 7.8% increase from 2023.
- Quest Diagnostics annual sg&a expenses for 2023 were $1.642B, a 12.38% decline from 2022.
|
Quest Diagnostics Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025 | $1,967 |
| 2024 | $1,770 |
| 2023 | $1,642 |
| 2022 | $1,874 |
| 2021 | $1,727 |
| 2020 | $1,550 |
| 2019 | $1,457 |
| 2018 | $1,424 |
| 2017 | $1,443 |
| 2016 | $1,380 |
| 2015 | $1,679 |
| 2014 | $1,728 |
| 2013 | $1,704 |
| 2012 | $1,745 |
| 2011 | $1,743 |
|
Quest Diagnostics Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $504 |
| 2025-12-31 | $504 |
| 2025-09-30 | $501 |
| 2025-06-30 | $486 |
| 2025-03-31 | $476 |
| 2024-12-31 | $466 |
| 2024-09-30 | $448 |
| 2024-06-30 | $416 |
| 2024-03-31 | $440 |
| 2023-12-31 | $407 |
| 2023-09-30 | $380 |
| 2023-06-30 | $416 |
| 2023-03-31 | $439 |
| 2022-12-31 | $563 |
| 2022-09-30 | $464 |
| 2022-06-30 | $422 |
| 2022-03-31 | $425 |
| 2021-12-31 | $464 |
| 2021-09-30 | $427 |
| 2021-06-30 | $429 |
| 2021-03-31 | $407 |
| 2020-12-31 | $447 |
| 2020-09-30 | $396 |
| 2020-06-30 | $360 |
| 2020-03-31 | $347 |
| 2019-12-31 | $349 |
| 2019-09-30 | $362 |
| 2019-06-30 | $362 |
| 2019-03-31 | $384 |
| 2018-12-31 | $356 |
| 2018-09-30 | $354 |
| 2018-06-30 | $351 |
| 2018-03-31 | $363 |
| 2017-12-31 | $382 |
| 2017-09-30 | $348 |
| 2017-06-30 | $358 |
| 2017-03-31 | $355 |
| 2016-12-31 | $99 |
| 2016-09-30 | $409 |
| 2016-06-30 | $430 |
| 2016-03-31 | $442 |
| 2015-12-31 | $429 |
| 2015-09-30 | $402 |
| 2015-06-30 | $429 |
| 2015-03-31 | $419 |
| 2014-12-31 | $427 |
| 2014-09-30 | $446 |
| 2014-06-30 | $440 |
| 2014-03-31 | $415 |
| 2013-12-31 | $415 |
| 2013-09-30 | $423 |
| 2013-06-30 | $418 |
| 2013-03-31 | $448 |
| 2012-12-31 | $421 |
| 2012-09-30 | $417 |
| 2012-06-30 | $424 |
| 2012-03-31 | $483 |
| 2011-12-31 | $386 |
| 2011-09-30 | $447 |
| 2011-06-30 | $463 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $21.197B | $11.035B |
| Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.514B | 13.37 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| DaVita (DVA) | United States | $10.023B | 13.82 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |